Home > Boards > Other Markets > Foreign Stock Markets > Novo Nordisk A/S (NVO)

FDA extends NDA review of NVO’s degludec and

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 739
Posts 112,977
Boards Moderated 17
Alias Born 09/05/02
160x600 placeholder
DewDiligence Member Level  Friday, 06/08/12 08:25:14 AM
Re: None
Post # of 49 
FDA extends NDA review of NVO’s degludec and degludecplus by three months:

#msg-76408031

The new PDUFA date is 10/29/12.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist